11th Congress of the European Menopause and Andropause Society, May 22-24, 2017, Amsterdam, the Netherlands

On Wednesday May 24, 2017 Pantarhei sponsored a symposium entitled “Estrogens for breast- and prostate cancer treatment”. Lectures were presented by Herjan Coelingh Bennink (High dose estrogens for breast cancer), Carole Verhoeven (Estetrol for breast cancer) and Yvette Zimmerman (Estetrol for prostate cancer). The session was chaired by Ludwig Kiesel and Cobi Reisman.

ENDO 2017, April 1-4, 2017 Orlando, USA, Press Release

The first weekend of April, Yvette Zimmerman, COO and Ellen Dutman, CRA at Pantarhei attended the ENDO congress in Orlando, USA, which is organised by the Endocrine Society. The results from a clinical study with estetrol in healthy men were presented in a poster session.

For more information please read the press release of the Endocrine Society. Read more

BioCapital Europe conference March 15, 2017, Amsterdam, the Netherlands

The CEO of Pantarhei, Herjan Coelingh Bennink, will be presenting at the BioCapital Europe Conference on March 15, 2017 in Amsterdam. An ideal opportunity to meet us and discuss possibilities to collaborate, partner with or invest in Pantarhei’s programmes.

17th World Congress of the Academy of Human Reproduction, March 15-18, 2017, Rome, Italy

On Friday March 17, 2017 Pantarhei will sponsor a symposium entitled “Estrogens for the treatment of breast cancer”. Lectures will be presented by Herjan Coelingh Bennink (Results of High Dose Estrogen (HDE) treatment of breast cancer), Richard Santen (Effect of estrogens in preclinical breast cancer models) and Andrea Genazzani (Breast cancer: molecular and hormonal basis of metastasis). The session will be chaired by Piero Sismondi.

15th St. Gallen International Breast Cancer Conference 2017, 15-18 March 2017, Vienna, Austria

The CSO of Pantarhei, Carole Verhoeven, will attend the St Gallen Breast Cancer Conference in Vienna. She will present a poster summarising the the design of the clinical study with estetrol in patients with advanced breast cancer (ABC E4 study). The hypothesis of this study is that the fetal estrogen estetrol may have anti-tumour effects in patients with advanced ER+ breast cancer and that it most likely will also improve patients quality of life by reducing symptoms of estrogen deficiency. This study will be conducted at three clinical sites in Germany. Enrolment is anticipated to start in April this year.

32nd Annual EAU Congress, March 24-28, 2017, London, UK

Pantarhei Oncology will be visiting the 32nd Annual EAU Congress in London. A poster presentation by Ellen Dutman, CRA at Pantarhei, on Saturday March 25th will show the results of a clinical study with the estrogen E4 in healthy men. The objective of the study was to investigate the efficacy and safety of estetrol for its potential use in the treatment of prostate cancer with special emphasis on the effect of estetrol on testosterone levels. The results suggest that E4 may be suitable for the treatment of advanced prostate cancer.

IMPRINT

Pantarhei Bioscience BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheibio.com

DISCLAIMER

The information contained in this website is for general information purposes only. The information is provided by Pantarhei Bioscience and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

SOCIAL MEDIA